Pomerantz Law Firm Launches Investigation into ACADIA Pharmaceuticals for Possible Securities Fraud

Investor Alert: Pomerantz Law Firm Investigates Claims Regarding ACADIA Pharmaceuticals

Pomerantz LLP has officially announced its investigation into claims involving investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). This investigation raises concerns regarding possible securities fraud or other illicit business practices by the company and some of its executives.

The inquiry comes after ACADIA's announcement on September 24, 2025, regarding the results of a Phase 3 clinical trial for its product, intranasal carbetocin (ACP-101), aimed at treating hyperphagia in patients diagnosed with Prader-Willi Syndrome (PWS). The company issued a press release detailing that the trial did not show statistically significant results in improving patient conditions compared to a placebo, and thus the development of the drug will not proceed.

This disappointing announcement led to a notable decrease in ACADIA's stock price, which fell by $2.34 per share, marking a decline of nearly 10%. Investors who feel impacted by this dip in stock value may want to explore their legal options.

Pomerantz LLP, a highly regarded law firm recognized for its commitment to holding corporations accountable for securities violations, invites investors affected by these events to reach out for more information. The firm has a storied history, successfully advocating for victims of corporate misconduct and securities fraud for over 85 years, making it a prominent force in this field. Notably, it was founded by Abraham L. Pomerantz, often referred to as a pioneer in class actions and securities law.

Given the gravity of the situation concerning ACADIA Pharmaceuticals, shareholders are encouraged to consider the implications of the investigation on their investments. Anyone interested in participating in the investigation can contact Pomerantz LLP directly through Danielle Peyton at [email protected] or by phone at 646-581-9980, extension 7980.

As this situation unfolds, further developments are likely to emerge. Investors will want to stay informed about any legal proceedings or updates that may arise from this investigation, especially concerning potential restitution or recoveries for losses incurred due to the alleged securities fraud.

In a market that is increasingly scrutinizing pharmaceutical advancements and their associated disclosures, cases like these underscore the importance of transparency and accountability within the biotech sector. The actions taken by law firms such as Pomerantz LLP are crucial in protecting the rights and investments of shareholders in cases where corporate integrity is called into question.

The ongoing investigation will shed light on whether ACADIA violated securities laws or engaged in any deceptive practices detrimental to shareholders. Investors are encouraged to monitor this case closely, as its outcome could have implications not only for ACADIA but for broader industry practices surrounding transparency and ethical conduct in pharmaceutical advancements.